Regeneron slump continues as analysts turn more cautious
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Morgan Stanley Reiterates Overweight Rating on Regeneron Pharma (REGN)
September 26, 2024 5:56 AM EDTMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $1,247.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Today the Federal Circuit issued an order to temporarily enjoin Amgen from launching its Eylea biosimilar until further notice. As a... More
Truist Securities Reiterates Buy Rating on Amgen (AMGN)
September 25, 2024 5:43 AM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $320.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "Earlier this evening, Amgen (AMGN, Buy) provided positive Ph3 updates from two key pipeline programs - Uplizna in gMG and rocatinlimab in atopic... More
Truist Securities on Regeneron Pharma (REGN): 'Buying opportunity'
September 24, 2024 2:18 PM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $1,200.00 price target on Regeneron Pharma (NASDAQ: REGN)
The analyst comments "We spoke with Regeneron (REGN, Buy) mgmt today who noted that they have appealed the court's decision as of last night, and... More
